BioAtla is changing the future of medicine and personalized health. Drawing on deep in house experience in protein and antibody engineering, we employ proprietary technologies to solve critical protein development challenges and produce novel, IP-protectable products both for our partners and our own product portfolio.
The culmination of our technological capabilities is our widely applicable platform technology known as Conditionally Active Biologics (CABs). CAB-designed monoclonal antibodies selectively bind their antigen when it is found in tumor tissue for example, but not when it is found in normal tissue. This approach enables improved safety and therapeutic index, and allows higher dosing and thus increased potency and sustained treatment. CAB technology also expands the universe of potential targets for oncology and other diseases by conferring greater specificity for diseased tissue.